Humoral and cellular responses to vaccine according to treatment received: comparison between cohort 1 (immunocompromised, IMRD ISP+) and cohort 2 (immunocompetent, IMRD ISP−)
| Antimalarials | IL-6i | TNFi | MTX | Abatacept | BMB | MFM | AZA | LFM | RTX | TNF/IL-6i+MTX | RTX+MTX | BMB+MTX | |
| n (%) | 19 (42) | 10 (22) | 10 (22) | 21 (21) | 10 (10) | 8 (8) | 10 (10) | 7 (7) | 6 (6) | 16 (16) | 7 (7) | 10 (10) | 5 (5) |
| Seroconversion rate (n, %) | 17 (89) | 9 (90) | 9 (90) | 13 (62) | 1 (10) | 4 (50) | 8 (80) | 4 (57) | 6 (100) | 5 (31) | 6 (85) | 3 (30) | 2 (40) |
| p* (cohort 1) | 0.04* | 0.11 | 0.12 | 0.96 | 0.008* | 0.47 | 0.26 | 0.91 | 0.18 | 0.03* | 0.26 | 0.05 | 0.09 |
| p** (cohort 2) | 0.40 | 0.49 | 0.49 | 0.04* | 0.001* | 0.04* | 0.76 | 0.18 | 0.60 | 0.007* | 0.77 | 0.003* | 0.01* |
| IgG anti-spike levels mean±SD (BAU/mL) | 594.3±264 | 611±272 | 543±298 | 313±291 | 13±37 | 255±241 | 323±250 | 178±142 | 572±228 | 133±263 | 356±246 | 123±208 | 232±198 |
| p* (cohort 1) | 0.19 | 0.31 | 0.32 | 0.71 | 0.004* | 0.72 | 0.003* | 0.28 | 0.21 | 0.07 | 0.267 | 0.04* | 0.81 |
| p** (cohort 2) | 0.97 | 0.79 | 0.61 | 0.02* | 0.002* | 0.04* | 0.03* | 0.01* | 0.92 | 0.002* | 0.77 | 0.01* | 0.03* |
| CD4 T-cell response (n, %) | 17 (89) | 8 (80) | 10 (100) | 17 (80) | 1 (10) | 5 (63) | 7 (70) | 3 (42) | 6 (100) | 8 (50) | 6 (85) | 5 (50) | 3 (60) |
| p* (cohort 1) | 0.03* | 0.22 | 0.07 | 0.08 | 0.03* | 0.88 | 0.11 | 0.64 | 0.16 | 0.49 | 0.20 | 0.55 | 0.99 |
| p** (cohort 2) | 0.19 | 0.71 | 0.17 | 0.56 | 0.003* | 0.47 | 0.27 | 0.08 | 0.45 | 0.08 | 0.52 | 0.14 | 0.49 |
| CD8 T-cell response (n, %) | 17 (89) | 8 (80) | 10 (100) | 16 (76) | 2 (20) | 5 (63) | 7 (70) | 3 (42) | 6 (100) | 8 (50) | 6 (85) | 5 (50) | 3 (60) |
| p* (cohort 1) | 0.03* | 0.19 | 0.06 | 0.12 | 0.15 | 0.78 | 0.17 | 0.60 | 0.49 | 0.58 | 0.18 | 0.65 | 0.91 |
| p† (cohort 2) | 0.19 | 0.49 | 0.17 | 0.88 | 0.01* | 0.55 | 0.52 | 0.08 | 0.17 | 0.08 | 0.52 | 0.13 | 0.49 |
p* refers to comparison between each treatment group with the rest of cohort 1 (IMRD ISP+).
p** refers to comparison between each treatment group with cohort 2 (IMRD ISP−).
AZA, azathioprine; BAU, binding antibody unit; BMB, belimumab; IL-6i, IL-6 inhibitors; IMRD, immune-mediated inflammatory rheumatic disease; LFM, leflunomide; MFM, mycophenolate; MTX, methotrexate; RTX, rituximab.